Detalhe da pesquisa
1.
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
Breast Cancer Res
; 25(1): 103, 2023 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37653397
2.
Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL.
Breast Cancer Res Treat
; 198(3): 545-553, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36807725
3.
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Ann Oncol
; 32(8): 1015-1024, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34102253
4.
Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024].
Ann Oncol
; 32(10): 1307, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34412950
5.
BOOP in Europe.
Chest
; 102(1 Suppl): 14S-20S, 1992 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-1623804